Completed PHASE4 INTERVENTIONAL NCT00557232

Intraocular Bevacizumab (Avastin) for Rubeosis Iridis

The RAVE (Rubeosis Anit-VEgf) Trial, Utilizes Monthly Intravitreal Bevazizumab (Avastin) Injections for 12 Months to See if Total VEGF Blockade Will Prevent Neovascular Glaucoma and Eliminate the Need for Panretinal Photocoagulation in Patients With Ischemic Central Retinal Vein Occlusion

Sponsor: Instituto de Olhos de Goiania

Conditions Glaucoma Rubeosis Iridis

Interventions bevacizumab

Updated 5 times since 2017 Last updated: Nov 25, 2011 Started: Nov 30, 2006 Primary completion: Oct 31, 2011 Completion: Nov 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Glaucoma and Rubeosis Iridis and is currently completed. Instituto de Olhos de Goiania leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Instituto de Olhos de Goiania

Data source: Instituto de Olhos de Goiania

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.